Press coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.8859512886318 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of brokerages have recently commented on SYRS. Zacks Investment Research lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Roth Capital began coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price objective on the stock. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 price objective on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. JMP Securities raised Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price on the stock in a report on Thursday, September 28th. Finally, ValuEngine lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $22.23.
Syros Pharmaceuticals (NASDAQ SYRS) traded up $0.30 on Thursday, reaching $10.82. The company’s stock had a trading volume of 166,200 shares, compared to its average volume of 244,736. The firm has a market cap of $282.42 and a price-to-earnings ratio of -6.22. Syros Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.53). sell-side analysts forecast that Syros Pharmaceuticals will post -2.12 earnings per share for the current fiscal year.
In other news, insider Jeremy P. Springhorn acquired 15,000 shares of Syros Pharmaceuticals stock in a transaction on Friday, December 15th. The stock was bought at an average price of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Srinivas Akkaraju acquired 109,774 shares of Syros Pharmaceuticals stock in a transaction on Thursday, December 14th. The stock was purchased at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Syros Pharmaceuticals (SYRS) Earns News Impact Score of 0.16” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/18/syros-pharmaceuticals-syrs-earns-news-impact-score-of-0-16.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.